+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of vonicog alfa, a recombinant von Willebrand factor rVWF, as a prevention treatment for children diagnosed with severe Von Willebrand Disease VWD. This Phase 3 study includes children who have previously been treated with VWF products or plasma-derived VWF pdVWF. The study is designed to assess how well vonicog alfa works over a 12-month treatment period. Participants are divided into three age groups under 6 years, 6 to under 12 years, and 12 to under 18 years. Each group will receive vonicog alfa by intravenous infusion twice weekly at an initial dose between 40 to 60 international units per kilogram IUkg. Treatment may also include ADVATE infusions as needed for bleeding episodes or surgical bleeding management. The treatment period lasts for 12 months with regular dosing and monitoring. During the study, participants will visit the clinic five times after starting treatment. Researchers will monitor bleeding rates, safety events, antibody development, vital signs, and blood levels of vonicog alfa and related factors. The main measure is the annualized bleeding rate during prophylactic treatment. Other assessments include adverse events, infusion details, and laboratory tests over the 12-month period to evaluate treatment impact and safety.

Age: 0 - 17YearsAll GendersPhase 3
23 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations
A

Actively Recruiting

Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.

Age: 12Years +All GendersPhase 3
256 locations
E

Actively Recruiting

Researchers are evaluating the safety and efficacy of ibuzatrelvir alone and in combination with remdesivir compared to remdesivir alone in treating symptomatic COVID-19 among severely immunocompromised adults. This Phase 3, randomized, double-blind study focuses on participants who are non-hospitalized or have mild-to-moderate COVID-19 at baseline. The trial aims to better understand treatment options for this vulnerable patient group who may face prolonged infections and severe illness progression. Participants are assigned to one of three groups ibuzatrelvir taken orally twice daily plus intravenous remdesivir, ibuzatrelvir plus intravenous placebo, or oral placebo plus intravenous remdesivir. The study uses matching placebos to maintain blinding. Treatment durations and specific dosing schedules are carefully monitored to compare the combination and monotherapy effects over the study period. During approximately 10 study visits over 24 weeks, participants will attend clinic visits for blood tests, nasal swabs collected both in-clinic and at home, and complete questionnaires. Researchers will assess outcomes such as symptom alleviation, viral RNA levels, rates of infection recurrence, hospital visits, and safety events. This comprehensive monitoring helps evaluate the impact of the treatments on COVID-19 symptoms and viral clearance in immunocompromised adults.

Age: 18Years +All GendersPhase 3
159 locations
M

Actively Recruiting

Researchers are evaluating the safety and effectiveness of various drug regimens for people with myasthenia gravis, a condition that affects muscle strength. This platform study uses a master protocol allowing multiple treatments to be tested separately but under a common framework. The goal is to find treatments that reduce side effects and improve quality of life. Participants may receive treatments including intravenous infusions of efgartigimod, empasiprubart, or placebo, as well as subcutaneous injections of efgartigimod PH20 using a pre-filled syringe. The study includes different treatment groups based on specific myasthenia gravis subtypes and prior responses to therapy. Each treatment period varies in length depending on the specific intervention appendix. Throughout the study, participants undergo screening, treatment, and follow-up periods lasting up to approximately seven years depending on the treatment group. Researchers will monitor safety and tolerability as the primary outcomes, along with evaluating how well the treatments work. Participants will have regular assessments and safety monitoring throughout their involvement in the platform study.

Age: 18Years +All Genders
37 locations
E

Actively Recruiting

Researchers are evaluating the safety and therapeutic relevance of empasiprubart as an add-on treatment to efgartigimod in people with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis who have only partially responded to efgartigimod. This Phase 2a exploratory study is part of the larger ADAPT Forward platform, aiming to find safer and more effective treatment approaches to reduce side effects and improve quality of life for patients with myasthenia gravis. Participants first enter a run-in period where they receive intravenous efgartigimod. Those eligible then move to the add-on period, receiving both efgartigimod and empasiprubart intravenously. Participants not eligible for the add-on phase continue with efgartigimod alone during the safety follow-up period. The entire study duration for each participant lasts up to about 54 weeks. Throughout the study, participants are closely monitored with assessments including adverse event tracking, muscle strength and function evaluations, and quality of life questionnaires. The primary outcome is the incidence of adverse events during the first 21 weeks, with secondary measures examining changes in clinical scores such as MG-ADL and QMG. Safety follow-up continues for those not in the add-on phase to ensure ongoing monitoring of treatment effects.

Age: 18Years +All GendersPhase 2
33 locations
L

Actively Recruiting

This research aims to evaluate the safety and tolerability of long-term use of Treprostinil Palmitil Inhalation Powder TPIP in participants with pulmonary hypertension associated with interstitial lung disease PH-ILD who have previously completed a related study. The purpose is to understand how well TPIP is tolerated over time and monitor any adverse effects while providing ongoing treatment. Participants who have finished the initial PH-ILD TPIP study will start with a 4-week double-dummy titration period using their stable dose combined with either TPIP or placebo. After this, they will receive open-label TPIP at a stable maintenance dose, with optional dose increases ranging from 80 to 1280 micrograms once daily, continuing for 104 weeks. Throughout the study, participants will be monitored regularly for treatment-emergent adverse events and changes in lung function, exercise capacity, biomarkers, and quality of life. Assessments include the 6-minute walk distance, forced vital capacity, forced expiratory volume, plasma concentrations of NT-proBNP, and questionnaires related to pulmonary fibrosis symptoms. Safety and effectiveness data will be collected up to 108 weeks, with ongoing monitoring of clinical worsening and major morbidity or mortality events.

Age: 18Years +All GendersPhase 3
11 locations

1-10 of 17

1